Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Abstract

A B S T R A C T PurposeTo determine the efficacy and safety of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia (AML). Patients and MethodsA phase II, open-label, multicenter study was conducted with single-agent clofarabine in pediatric patients with refractory or relapsed AML. Clofarabine was administered intravenously over 2 hours at the pediatric maximum-tolerated dose (MTD) of 52 mg/m 2 daily for 5 consecutive days. Cycles were repeated every 2 to 6 weeks. Responses determined by an independent response review panel. ResultsThe 42 patients treated on the study had a median age of 13 years (range, 2 to 22 years) and had received a median number of two (range, one to five) prior regimens. The response rate was 26% and included one complete response without platelet recovery and 10 partial responses. The median duration of response was 20 weeks (range, 2 to Ն 156 weeks). Six of 28 patients who were refractory to the immediately preceding therapy achieved response. Thirteen patients (31%), including seven responders, proceeded to hematopoietic stem-cell transplantation (HSCT) after treatment with clofarabine and survived between 24 to Ն 160 weeks. Five patients (12%) remain alive post-transplantation at Ն 63, Ն 71, Ն 86, Ն 114, and Ն 130 weeks. The most common grade 3 or greater adverse events without regard to causality were febrile neutropenia, catheter-related infection, epistaxis, hypotension, nausea, and fever. Transient elevation of liver enzymes and hypokalemia occurred frequently. Five patients died within 30 days of clofarabine administration secondary to progressive disease, and another five died as a result of an adverse event. ConclusionClofarabine is active in pediatric patients with multiply relapsed or refractory AML. Responses allowed several refractory patients to proceed to HSCT. The toxicity profile was expected in this patient population.

Acute metabolic encephalopathy in two patients treated with asparaginase and ondasetron

“…PD-1 has also been detected in several types of T-cell non-Hodgkin lymphoma, including angioimmunoblastic T-cell lymphoma, adult T-cell leukemia lymphoma, and peripheral T-cell lymphoma/leukemia [4][5][6][7]. Because PD-1 expression by malignant cells in CTCL, particularly Sé zary syndrome, has not been previously characterized, we aimed to determine the frequency of expression of this marker in mycosis fungoides and Sé zary syndrome.…”

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab

“…7,8 Moreover, with duration and progression of relapsed ALL, treatment faces multi-drug resistance which constitutes an unsolved problem. [13][14][15] Therefore, new therapeutics with known but also alternative mode of action and lower toxicity profile are necessary. [16][17][18][19] The novel class of bispecific single-chain antibody construct (BiTE) blinatumomab is currently under investigation.…”

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia

“…After induction chemotherapy, we introduced a consolidation cycle that incorporated clofarabine, previously demonstrated to be well-tolerated in older adults and efficacious against ALL, as well as prednisone and asparaginase. 33,34 Following these initial two courses of treatment, patients, regardless of cytogenetics or other risk profiles, could proceed to allogeneic HCT. Those who did not undergo HCT remained on study to receive subsequent therapy.…”